In yesterday’s Wall Street session, Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) shares traded at $9.61, down -6.79% from the previous session.
As of this writing, 3 analysts cover Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $20.00 and a low of $9.00, we find $15.00. Given the previous closing price of $10.31, this indicates a potential upside of 45.49 percent. IRWD stock price is now -10.97% away from the 50-day moving average and -13.39% away from the 200-day moving average. The market capitalization of the company currently stands at $1.48B.
There are 1 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $14.67 as their price target over the next twelve months.
With the price target of $15, CapitalOne recently initiated with Overweight rating for Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD).
In other news, MCCOURT Thomas A, Chief Executive Officer sold 26,632 shares of the company’s stock on May 30. The stock was sold for $284,962 at an average price of $10.70. Upon completion of the transaction, the Chief Executive Officer now directly owns 758,284 shares in the company, valued at $7.29 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 22, Chief Executive Officer MCCOURT Thomas A sold 36,000 shares of the business’s stock. A total of $364,320 was realized by selling the stock at an average price of $10.12. This leaves the insider owning 784,916 shares of the company worth $7.54 million. Insiders disposed of 585,510 shares of company stock worth roughly $5.63 million over the past 1 year. A total of 1.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IRWD stock. A new stake in Ironwood Pharmaceuticals Inc. shares was purchased by BALYASNY ASSET MANAGEMENT L.P. during the first quarter worth $9,137,000. BRANDYWINE GLOBAL INVESTMENT MANAGEMENT, LLC invested $4,883,000 in shares of IRWD during the first quarter. In the first quarter, TWINBEECH CAPITAL LP acquired a new stake in Ironwood Pharmaceuticals Inc. valued at approximately $1,921,000. ALPHACENTRIC ADVISORS LLC acquired a new stake in IRWD for approximately $1,514,000. SQUAREPOINT OPS LLC purchased a new stake in IRWD valued at around $1,469,000 in the second quarter. In total, there are 361 active investors with 105.26% ownership of the company’s stock.
Wednesday morning saw Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) opened at $10.31. During the past 12 months, Ironwood Pharmaceuticals Inc. has had a low of $9.73 and a high of $12.66. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 36.30, and a quick ratio of 36.30. The fifty day moving average price for IRWD is $10.77 and a two-hundred day moving average price translates $11.09 for the stock.
The latest earnings results from Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) was released for Jun, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.31, beating analysts’ expectations of $0.25 by 0.06. This compares to $0.20 EPS in the same period last year. The net profit margin was 43.60% and return on equity was 29.30% for IRWD. The company reported revenue of $104.06 million for the quarter, compared to $97.53 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 6.7 percent. For the current quarter, analysts expect IRWD to generate $112.99M in revenue.
